WallStSmart
PBM

Psyence Biomedical Ltd. Common Shares

NASDAQ: PBM · HEALTHCARE · BIOTECHNOLOGY

$5.27
-6.58% today

Updated 2026-06-04

Market cap
$7.64M
P/E ratio
P/S ratio
EPS (TTM)
$-389.98
Dividend yield
52W range
$2 – $75
Volume
3.0M

Psyence Biomedical Ltd. Common Shares (PBM) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20212022202320242025
Total assets$4.90M$326.55M$258.93M$1.13M$7.32M
Cash & equivalents$4.75M$431905.00$15956.00$762799.00$6.14M
Current assets$4.90M$797196.00$1.21M$1.13M$6.56M
Total liabilities$101078.00$16.38M$14.27M$12.10M$594366.00
Current liabilities$101078.00$142674.00$14.27M$12.10M$594366.00
Long-term debt
Shareholder equity$4.80M$236.65M$244.66M$-10.97M$6.72M
Retained earnings$-18.36M$-13.90M$-57.46M$-56.45M
Accounts receivable$138068.00$39546.00$60898.00$41747.00$137348.00
Inventory$-39546.00$1.00$-29611.00
Goodwill

Frequently asked questions

How much free cash flow does PBM generate?

PBM produced $-3.74M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PBM's balance sheet healthy?

PBM holds $6.14M in cash and equivalents against — in long-term debt, on $6.72M of shareholder equity. That debt is best read against the cash flow the business throws off each year.